Video Interview | Howie McKibbon

Botanix’s Chief Commercial Officer, Howie McKibbon, was interviewed on Ausbiz this week to discuss the positive results from our BTX 1702 Phase 1b/2 clinical trial for rosacea. 

Investor Webinar | May 2022

Botanix Pharmaceuticals (ASX: BOT) hosted an investor update webinar following the announcement of its acquisition of Sofpironium Bromide, the first and only novel treatment for primary axillary hyperhidrosis. Present on the call was President and Executive Chairman, Vince Ippolito; Executive Director, Matt Callahan; Chief Medical Adviser, Dr Patricia Walker; and Chief Commercial Officer, Howie McKibbon. 

Video Interview | Vince Ippolito

Botanix President and Executive Chairman, Vince Ippolito, is a world-leading dermatology executive.

In this video, he explains why today’s announcement of our acquisition of Sofpironium Bromide is such a promising commercial opportunity for Botanix – as the first and only new chemical entity developed for the treatment of primary axillary hyperhidrosis.

Small Caps Interview | Vince Ippolito

Botanix Pharmaceuticals (ASX: BOT) executive chairman Vince Ippolito joins Kerry Stevenson on Small Caps to discuss the company’s acquisition of novel dermatology asset Sofpironium Bromide gel.